We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-10.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.32B
AUM Growth
+$99.8M
Cap. Flow
+$327M
Cap. Flow %
24.74%
Top 10 Hldgs %
52.92%
Holding
77
New
22
Increased
20
Reduced
12
Closed
19

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$86.8M
2
RAD
Rite Aid Corporation
RAD
+$67.2M
3
PEN icon
Penumbra
PEN
+$63.2M
4
SAGE
Sage Therapeutics
SAGE
+$52.5M
5
INCY icon
Incyte
INCY
+$50.3M

Top Sells

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$85.4M
2
AGN
Allergan plc
AGN
+$41.5M
3
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$36.3M
4
HCA icon
HCA Healthcare
HCA
+$35.4M
5
ABBV icon
AbbVie
ABBV
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Miscellaneous 9.13%
3 Communication Services 1.09%
4 Industrials 1%
5 Technology 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OXFD
26
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$13.9M 1.05%
1,028,132
-184,760
-15% -$2.5M
CFMS
27
DELISTED
Conformis, Inc. Common Stock
CFMS
$12.4M 0.94%
+27,554
New +$13.9M
GBT
28
DELISTED
Global Blood Therapeutics, Inc.
GBT
$11.1M 0.84%
+262,892
New +$12.4M
FATE icon
29
Fate Therapeutics
FATE
$291M
$11.1M 0.84%
2,074,836
+67,390
+3% +$460K
HNT
30
DELISTED
HEALTH NET INC
HNT
$10.8M 0.82%
179,229
-208,899
-54% -$13.8M
TNET icon
31
TriNet
TNET
$3.23B
$10.7M 0.81%
+639,186
New +$13.1M
CASC
32
DELISTED
Cascadian Therapeutics, Inc.
CASC
$9.9M 0.75%
602,498
-91,648
-13% -$1.88M
PRQR icon
33
ProQR Therapeutics
PRQR
$323M
$9.63M 0.73%
660,816
+144,126
+28% +$2.41M
BPMC
34
DELISTED
Blueprint Medicines
BPMC
$7.84M 0.59%
367,485
-10,750
-3% -$297K
TRIV
35
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$7.32M 0.55%
1,463,983
-580
-0% -$3.12K
CERS icon
36
Cerus
CERS
$534M
$7.28M 0.55%
1,603,427
– –
NGNE icon
37
Neurogene
NGNE
$732M
$7.24M 0.55%
+25,715
New +$5.92M
ADVM
38
DELISTED
Adverum Biotechnologies
ADVM
$6.17M 0.47%
74,842
+21,114
+39% +$2.7M
RGNX icon
39
Regenxbio
RGNX
$638M
$6.1M 0.46%
+277,000
New +$7.07M
DRRX
40
DELISTED
DURECT Corp
DRRX
$5.1M 0.39%
+261,332
New +$5.94M
INFI
41
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.99M 0.38%
+590,100
New +$5.44M
NVTA
42
DELISTED
Invitae Corporation
NVTA
$4.77M 0.36%
660,129
+478,905
+264% +$5.03M
CSLT
43
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$3.08M 0.23%
734,397
-1,250,234
-63% -$7.89M
CCXI
44
DELISTED
ChemoCentryx, Inc.
CCXI
$3.03M 0.23%
500,615
+24,322
+5% +$176K
PGND
45
DELISTED
PRESS GANEY HOLDINGS INC COM STK (DE)
PGND
$2.51M 0.19%
+84,966
New +$2.59M
CARM
46
DELISTED
Carisma Therapeutics
CARM
$2.04M 0.15%
42,418
-20,645
-33% -$1.27M
IRWD icon
47
Ironwood Pharmaceuticals
IRWD
$682M
$1.99M 0.15%
+227,802
New +$2.13M
NVRO
48
DELISTED
NEVRO CORP.
NVRO
$1.16M 0.09%
+25,000
New +$1.21M
GNCA
49
DELISTED
Genocea Biosciences, Inc.
GNCA
$628K 0.05%
11,456
-66,484
-85% -$6.59M
XBI icon
50
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$576K 0.04%
+9,250
New +$729K
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2015 Portfolio in Review

As of Q3 2015, Redmile Group held 77 positions worth $1.32B, up 8.2% from $1.22B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group deployed $327M of net new capital in Q3 2015, opening 22 new positions and adding to 20 existing holdings. Its largest new stake was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $25.7M trimmed.

  • Redmile Group's largest Q3 2015 buy was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.
  • Redmile Group added most to Sage Therapeutics in Q3 2015, an estimated $52.5M increase.
  • Redmile Group's biggest Q3 2015 reduction was Jazz Pharmaceuticals, cutting an estimated $25.7M.
  • Redmile Group fully exited Bausch Health in Q3 2015, selling an estimated $85.4M.
  • Redmile Group's ten largest holdings make up 53% of its $1.32B portfolio in Q3 2015.
  • Redmile Group opened 22 new positions and closed 19 in Q3 2015.
  • Redmile Group's portfolio value rose 8.2% quarter-over-quarter to $1.32B.

Based on Redmile Group's 13F filing for Q3 2015, filed 17 Nov 2015.